FIT Biotech appoints Dr. Milla Koistinaho as Chief Operating Officer – FIT Biotech

Reports and Releases

FIT Biotech appoints Dr. Milla Koistinaho as Chief Operating Officer

FIT Biotech Ltd (NASDAQ: FITBIO), a Finnish biotechnology company, today announced the appointment of Adjunct Professor Milla Koistinaho, Ph.D. to the newly created position of Chief Operating Officer. In this role, she will oversee research and business development efforts for the Company. Dr. Koistinaho brings over 15 years of R&D and management experience. She will start in her new role at FIT Biotech in the beginning of August.

"I am very pleased to have in our team an experienced executive with a track record of building commercial operations based on innovative research and development in the pharmaceutical and biotech industry. We believe Dr. Koistinaho's expertise will be a crucial asset as we advance our R&D programs and commercialize the results thereof," said Dr. Kalevi Reijonen, CEO of FIT Biotech.

"I am delighted to join the FIT Biotech team during this period of the company development," remarked Dr. Koistinaho. "It is an exciting time, and I'm looking forward to meet the challenges of commercialization of the valuable product portfolio."

Alongside with her duties, Dr. Koistinaho will continue to advice Aplagon Oy in R&D, until 31.12.2015. Dr Koistinaho has previously served as CEO at Medeia Therapeutics Ltd. Prior to Medeia she served as CEO and CSO of Cerebricon Ltd, a contract research company. Prior to her experience with Cerebricon she worked as a post doctoral fellow at Eli Lilly, USA. Dr. Koistinaho received her Ph.D. in Biotechnology from the University of Kuopio, Finland.

Additional information:

CEO Kalevi Reijonen, FIT Biotech Oy
Phone: +358 40 843 5695

FIT Biotech Oy in brief:

FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology. Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development. FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at


The information contained herein is not for publication or distribution, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, South Africa or the United States. These written materials do not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. No part of the company shares or any other securities will be registered in the United States nor will the securities be offered to the public in the United States.

In certain states, the issue, use and/or sale of securities is subject to special legal or legislative restrictions. The Company or its advisors assumes no responsibility in the event there is a violation by any person of such restrictions.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published or offering circular distributed by the Company.

The Company has not given authorisation for offering the securities to the public in any other member state of the European Economic Area than Finland. Save for Finland, measures for offering the securities to the public have not been and will not be taken in any member state of the European Economic Area having implemented the Prospectus Directive (each a 'Relevant Member State') in a way that would require the publication of a prospectus in the Relevant Member State. As a consequence, the securities can only be offered in the Relevant Member States to (a) legal persons that are qualified investors as defined in the Prospectus Directive or (b) in any other situation mentioned in Article 3(2) of the Prospectus Directive. In this paragraph, the expression 'offer securities to the public' means communication by any means presenting sufficient information on the terms of the offer and the securities to be offered, so as to enable an investor to decide to use, purchase or subscribe to these securities, as the expression may vary due to the implementation measures taken in the Member State. The expression 'Prospectus Directive' refers to Directive 2003/71/EC (as amended, including the 2010 Amending Directive, to the extent that it has been implemented in the Relevant Member State), and it includes all relevant implementation measures in the Relevant Member State, and the expression '2010 Amending Directive' refers to Directive 2010/73/EC.

The information presented herein is targeted only at (i) persons outside the United Kingdom or (ii) persons with professional investment experience in the manner referred to in Article 19(5) of the United Kingdom Financial Services and Markets Act (Financial Promotion) Order 2005 and (iii) high net worth entities specified in Article 49(2) of the Order or other persons to which the document can be lawfully communicated (all jointly the 'Relevant Persons'). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.

Back to list